Semaglutide
- Status
- FDA Approved
- Evidence
Approved, human phase 3, graded on the Fat Loss Peptides Bench
It is a 31-amino-acid peptide analog of human GLP-1(7-37) with two key structural modifications: an alpha-aminoisobutyric acid (Aib) substitution at position 8 that confers resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, and a C18 fatty diacid chain attached via a linker at position 26 (lysine) that enables non-covalent binding to serum albumin.
Reviewed
01Overview
What Semaglutide is
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a molecular weight of 4113.58 Da and CAS number 910463-68-2. This albumin binding dramatically extends the half-life to approximately 7 days, enabling once-weekly subcutaneous dosing (PMID: 33567185).
Read the full overviewShow less
Semaglutide is FDA-approved under three brand names: Ozempic (subcutaneous injection for type 2 diabetes mellitus), Wegovy (weekly injection, and since 22 December 2025 a daily tablet, for chronic weight management and cardiovascular risk reduction), and Rybelsus (oral tablet for type 2 diabetes). Ozempic was approved in 2017, Wegovy in 2021, and Rybelsus in 2019, making semaglutide one of the most commercially significant pharmaceutical developments of the 2020s.
The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program established semaglutide as a transformative obesity treatment. In the STEP 1 trial, participants receiving semaglutide 2.4 mg weekly achieved a mean body weight reduction of 14.9% from baseline at 68 weeks, compared to 2.4% with placebo — a treatment difference of 12.4 percentage points (PMID: 33567185). The STEP 5 trial demonstrated durability of weight loss with continued treatment over 104 weeks, with participants maintaining approximately 15% total body weight loss (PMID: 36216945).
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial was a landmark cardiovascular outcomes study that demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in adults aged 45 or older with established cardiovascular disease and overweight or obesity but no diabetes, who received semaglutide 2.4 mg weekly versus placebo over a mean follow-up of 39.8 months (PMID: 37952131). This was the first trial to demonstrate cardiovascular benefit of a weight management drug in a non-diabetic population, fundamentally changing the clinical paradigm around obesity pharmacotherapy.
Oral semaglutide (Rybelsus) uses the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) to enable GI absorption of the peptide. Despite low bioavailability (~1%), the oral formulation achieves clinically meaningful glycemic control in type 2 diabetes. Oral semaglutide is FDA-approved for weight loss as Wegovy tablets (1.5, 4, 9 and 25 mg; approved 22 December 2025), for weight management in adults and for cardiovascular risk reduction in adults with established cardiovascular disease. In OASIS 4, mean weight loss at 64 weeks was 13.6% on 25 mg against 2.4% on placebo for all randomized patients (intention-to-treat, Wegovy label). The 50 mg dose tested in OASIS 1 is not approved.
Semaglutide represents a first-in-class efficacy level among GLP-1 receptor agonists for both glycemic control and weight reduction, with a well-characterized safety profile across tens of thousands of clinical trial participants and millions of post-marketing prescriptions.
How it works
GLP-1 Receptor Agonism and cAMP Signaling
Semaglutide binds to the GLP-1 receptor (GLP-1R), a class B G-protein coupled receptor expressed on pancreatic beta cells, hypothalamic neurons, gastric smooth muscle, cardiac myocytes, and other tissues. Upon binding, GLP-1R activates adenylyl cyclase via Gs-protein coupling, increasing intracellular cyclic AMP (cAMP) levels. In pancreatic beta cells, elevated cAMP activates protein kinase A (PKA) and exchange protein activated by cAMP (Epac2), which together amplify glucose-dependent insulin secretion through closure of KATP channels, calcium influx, and enhanced exocytosis of insulin granules.
Read the full mechanismShow less
Glucose-Dependent Insulin Secretion and Glucagon Suppression
A critical safety feature of GLP-1R agonism is its glucose-dependent mechanism: insulin secretion is stimulated only when blood glucose is elevated above fasting levels, minimizing hypoglycemia risk. Simultaneously, semaglutide suppresses glucagon secretion from pancreatic alpha cells in a glucose-dependent manner. This dual effect - enhanced insulin plus reduced glucagon - contributes to significant HbA1c reduction in type 2 diabetes (typically 1.5-1.8% with semaglutide 1.0 mg weekly in the SUSTAIN program). The glucose-lowering effect plateaus at normoglycemia, providing an inherent safety buffer.
Hypothalamic Appetite Suppression
Semaglutide reaches GLP-1 receptors in the hypothalamic arcuate nucleus and paraventricular nucleus - key brain regions that regulate appetite and energy homeostasis - primarily via circumventricular organs and adjacent fenestrated regions rather than by freely crossing the blood-brain barrier. It activates pro-opiomelanocortin (POMC) neurons that promote satiety and inhibits neuropeptide Y (NPY)/agouti-related peptide (AgRP) neurons that drive hunger. It also acts on GLP-1 receptors in the mesolimbic reward system (nucleus accumbens, ventral tegmental area), reducing food reward and hedonic eating. The net effect is reduced food cravings and a shift in food preference toward lower-calorie options.
Delayed Gastric Emptying
Semaglutide slows gastric emptying, prolonging gastric distension after meals and enhancing satiety signals via vagal afferents. This contributes to reduced caloric intake but also underlies the most common side effects (nausea, vomiting). Gastric emptying delay is most pronounced during dose titration and typically attenuates with continued treatment.
Cardiovascular Protection
The SELECT trial demonstrated that semaglutide's cardiovascular benefit extends beyond weight loss and glycemic control. Proposed mechanisms include anti-inflammatory effects on the vascular endothelium, reductions in C-reactive protein (CRP) and other markers of systemic inflammation, and improvements in blood pressure and lipid profile - suggesting anti-atherosclerotic activity that is only partly explained by weight loss.
Studied for
- Obesity
- Type 2 diabetes
- Cardiovascular disease
- NASH/MAFLD
- Kidney disease
Benefits listed
- Mean body weight reduction of 14.9% at 68 weeks in STEP 1 trial (PMID: 33567185)
- Sustained weight loss of ~15% (-15.2%) maintained through 104 weeks in STEP 5 trial (PMID: 36216945)
- 20% relative reduction in major adverse cardiovascular events (HR 0.80) in the SELECT trial (PMID: 37952131)
- HbA1c reduction of 1.5-1.8% in type 2 diabetes (SUSTAIN program)
Show 3 moreShow less
- Reduction in systemic inflammation (lower hs-CRP) observed in SELECT
- Available in both subcutaneous (weekly) and oral (daily) formulations
- Improved cardiometabolic risk factors including blood pressure and lipid profile
02Research
Free with emailWhat the research shows
Graded on a research bench
Reference pages that put Semaglutide next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.
Unlock the research summary
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- A summary of the key research
- Safety and side effects
- A link to the PubMed results
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
03Safety
Semaglutide side effects and interactions
Side effects
Common
- Nausea (most common, affects 20-44% of patients, dose-dependent)
- Vomiting (typically during dose titration, resolves with continued use)
- Diarrhea and constipation
- Abdominal pain and dyspepsia
- Injection site reactions (subcutaneous formulation)
Serious events
- Pancreatitis (rare but reported — discontinue if suspected)
- Gallbladder disorders including cholelithiasis (gallstones) with rapid weight loss
- Medullary thyroid carcinoma (MTC) risk — boxed warning based on rodent thyroid C-cell tumors
- Acute kidney injury (dehydration-mediated, usually from severe GI side effects)
- Diabetic retinopathy worsening with rapid glycemic improvement in T2D patients
- Suicidal behavior and ideation: no longer a label warning (removed from the Wegovy label in February 2026)
Who should not use it
Contraindications
Personal or family history of medullary thyroid carcinoma (MTC). Multiple endocrine neoplasia syndrome type 2 (MEN 2). History of pancreatitis. Severe gastrointestinal disease. Type 1 diabetes. Pregnancy or breastfeeding. Eating disorders (may exacerbate restriction).
Interactions
6 pairings in our record: 2 to avoid, 3 with a caution and 1 to monitor.
Tirzepatide
AvoidBoth are GLP-1 receptor agonists — do not combine due to additive effects and severe GI risk
Retatrutide
AvoidTriple agonist that includes GLP-1 — do not stack with semaglutide
Cagrilintide
CautionCagriSema is a studied combination, but requires medical supervision and adjusted dosing
Tesofensine
CautionBoth suppress appetite through different mechanisms — risk of excessive weight loss and malnutrition
MK-677
CautionMK-677 increases appetite and insulin resistance — may counteract semaglutide benefits
Metformin
MonitorBoth affect glucose metabolism — monitor blood sugar closely if combining
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
Need bloodwork before starting?
Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.
04Dosing
Free with emailSemaglutide dosage and protocols
- Dose range
- Diabetes (Ozempic): 250-1000 mcg weekly; Weight management (Wegovy): 2400 mcg weekly (after 16-week titration); Oral (Rybelsus): 3-14 mg daily
- Dosing
- Once weekly subcutaneous injection
- Common vials
- 3mg, 5mg, 10mg
Unlock the dosing protocols
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- Dose, route, how often and how long
- A titration schedule
- Beginner, intermediate and advanced protocols
- Reconstitution and handling notes
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
05Prices
Semaglutide prices
12 listings from 6 vendors, opening in the Featured order.
- Pack prices
- $39.00 to $174.99
- Lowest per mg
- $3.30/mg
- Vendors
- 6
- Listings
- 12 (vial, pen)
Prices as the vendors list them, last recorded 27 October 2026.
| Vendor | Product | Price | Buy |
|---|---|---|---|
RC-1S 30mg vial, 30mg vial In stock | $5.83/mg $174.99 | Buy RC-1S 30mg at ResearchChemHQ | |
Pep-1S 5mg (Semaglutide) vial, 5mg In stock | $12.00/mg $59.99 | Buy Pep-1S 5mg (Semaglutide) at Optimum Formula | |
Pep-1S 30mg (Semaglutide) vial, 1 vial In stock | $5.83/mg $174.99 | Buy Pep-1S 30mg (Semaglutide) at Optimum Formula | |
Semaglutide 10 mg pen (sold as GLP-1 SM Pen) pen, 1 pen In stock | $14.00/mg $139.99 | Buy Semaglutide 10 mg pen (sold as GLP-1 SM Pen) at Disguised Alpha | |
Semaglutide (ION-1S) 5mg vial, 1 vial In stock | $7.80/mg $39.00 | Buy Semaglutide (ION-1S) 5mg at Ion Peptide | |
Semaglutide (ION-1S) 10mg vial, 1 vial In stock | $5.50/mg $55.00 | Buy Semaglutide (ION-1S) 10mg at Ion Peptide | |
Semaglutide (ION-1S) 20mg vial, 1 vial Out of stock | $3.45/mg $69.00 | View Semaglutide (ION-1S) 20mg at Ion Peptide | |
Semaglutide (ION-1S) 30mg vial, 1 vial In stock | $3.30/mg $99.00 Lowest per mg | Buy Semaglutide (ION-1S) 30mg at Ion Peptide | |
Semaglutide 5mg vial, 5mg In stock | $19.00/mg $94.99 | Buy Semaglutide 5mg at BioMyst Labs | |
GLP-1S (Semaglutide) 2mg vial, 2mg vial In stock | $34.99/mg $69.99 | Buy GLP-1S (Semaglutide) 2mg at Half Nattys | |
GLP-1S (Semaglutide) 5mg vial, 5mg vial In stock | $20.00/mg $99.99 | Buy GLP-1S (Semaglutide) 5mg at Half Nattys | |
GLP-1S (Semaglutide) 10mg vial, 10mg vial In stock | $16.00/mg $159.99 | Buy GLP-1S (Semaglutide) 10mg at Half Nattys |
Vendors selling Semaglutide(6: trust score, certificates, payment, shipping)
- Ion Peptide4 listings, from $39.00
Trust Score 70/100, no certificate records on file, pays by card, crypto, ACH, ships to the US, international destinations
- Optimum Formula2 listings, from $59.99
Trust Score 100/100, 4 of 6 certificate records read, pays by card, crypto, ships to the US
- Half Nattys3 listings, from $69.99
Trust Score 50/100, 0 of 31 certificate records read, pays by card, crypto, Zelle, ships to the US
- BioMyst Labs1 listing, from $94.99
Trust Score 70/100, no certificate records on file, pays by card, crypto, ships to the US, international destinations
- Disguised Alpha1 listing, from $139.99
Trust Score 50/100, 0 of 36 certificate records read, pays by card, crypto, bank transfer, ships to the US, the EU, the UK
- ResearchChemHQ1 listing, from $174.99
Trust Score 100/100, 6 of 6 certificate records read, pays by card, crypto, ships to the US
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors
Price history(4 days with a recorded price)
06Chemistry
Chemistry and structure
- Molecular formula
- C187H291N45O59
- Molecular mass
- 4113.58 g/mol
- CAS number
- 910463-68-2
- IUPAC name
- N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetamido]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37)-peptide
- Amino acid sequence
- HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG (31-residue analog of human GLP-1(7-37); X at position 8 = Aib, 2-aminoisobutyric acid). Key modifications vs native GLP-1: Ala8->Aib (confers DPP-4 resistance), Lys34->Arg, and the Lys26 side chain is acylated with a C18 fatty diacid (octadecanedioic acid) via a gamma-Glu / 2x AEEA (8-amino-3,6-dioxaoctanoic acid) linker, enabling strong albumin binding and a ~1-week half-life. Molecular formula C187H291N45O59; average molecular weight ~4113.6 Da.
- Half-life
- ~7 days (168 hours), enabled by C18 fatty diacid albumin-binding modification
08Questions
Frequently asked questions
How is semaglutide dosed for weight loss?
The Wegovy schedule climbs once a week: 0.25 mg for the first four weeks, then 0.5, 1, 1.7, and 2.4 mg as the maintenance dose, moving up about every four weeks. The 0.25 mg start is there to settle your stomach, not to drive results. Move up only once side effects calm down.
What is the difference between Ozempic and Wegovy?
Same drug, semaglutide, with different branding and approved doses. Ozempic is the type-2-diabetes brand; Wegovy is the weight-management brand and goes to a higher 2.4 mg dose. The molecule is identical.
Why does semaglutide cause nausea?
GLP-1 drugs slow how fast your stomach empties, which is part of how they curb appetite, and that is what drives the nausea. It is dose-related and usually fades. Titrating up slowly is the main way to keep it manageable.
How many vendors sell Semaglutide, and what does it cost per mg?
6 of the vendors BodyHackGuide tracks list Semaglutide (12 listings). Among BodyHackGuide's Semaglutide listings recorded as in stock with a milligram count, the lowest price per milligram is $3.30/mg at Ion Peptide and the median is $12.00/mg. The Semaglutide prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a Semaglutide listing is dated 27 October 2026.
Which vendors have third-party COAs for Semaglutide on file at BodyHackGuide?
BodyHackGuide holds 102 third-party certificate records for Semaglutide, from ResearchChemHQ and Half Nattys. An editor has read 1 of BodyHackGuide's 102 certificate records for Semaglutide and recorded the laboratory, the compound and the test date as printed on each. The laboratories named on BodyHackGuide's Semaglutide certificate records are Janoshik Analytical and Freedom Diagnostics Testing, and the newest test date on them is 6 October 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.
Related
Articles on Semaglutide
- The 8 Best Peptide Companies for Research: 2026 Purity & Price Comparisonvendor-reviews, 16 September 2026
- Myostatin: The Muscle Brake, the Inhibitors, and What Actually Works (2026)Guides, 9 July 2026
- Aquasome Nanotechnology and Oral Peptides: The Mechanism, the Research, and the 10 Compounds It Actually Works ForResearch, 20 May 2026
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.





